|
1
|
Bacci G, Balladelli A, Palmerini E, et al:
Neoadjuvant chemotherapy for osteosarcoma of the extremities in
preadolescent patients: the Rizzoli Institute experience. J Pediatr
Hematol Oncol. 30:908–912. 2008.
|
|
2
|
Bacci G, Rocca M, Salone M, et al: High
grade osteosarcoma of the extremities with lung metastases at
presentation: treatment with neoadjuvant chemotherapy and
simultaneous resection of primary andmetastatic lesions. J Surg
Oncol. 98:415–420. 2008.
|
|
3
|
Franke M, Hardes J, Helmke K, et al:
Solitary skeletal osteosarcoma recurrence. Findings from the
Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer.
56:771–776. 2011.
|
|
4
|
Andreou D, Bielack SS, Carrle D, et al:
The influence of tumor- and treatment-related factors on the
development of local recurrence in osteosarcoma after adequate
surgery. An analysis of 1355 patients treated on neoadjuvant
Cooperative Osteosarcoma Study Group protocols. Ann Oncol.
22:1228–1235. 2011.
|
|
5
|
Routt SM, Zhu J, Zaleski JM and Dynlacht
JR: Potentiation of metalloenediyne cytotoxicity by hyperthermia.
Int J Hyperthermia. 27:435–444. 2011.
|
|
6
|
Streckfus CF, Brown RE and Bull JM:
Proteomics, morphoproteomics, saliva and breast cancer: an emerging
approach to guide the delivery of individualised thermal therapy,
thermochemotherapy and monitor therapy response. Int J
Hyperthermia. 26:649–661. 2010.
|
|
7
|
Trieb K, Blahovec H and Kubista B: Effects
of hyperthermia on heat shock protein expression, alkaline
phosphatase activity and proliferation in human osteosarcoma cells.
Cell Biochem Funct. 25:669–672. 2007.
|
|
8
|
Fan QY, Ma BA, Zhou Y, et al: Bone tumors
of the extremities or pelvis treated by microwave-induced
hyperthermia. Clin Orthop Relat Res. 406:165–175. 2003.
|
|
9
|
Shido Y, Nishida Y, Suzuki Y, et al:
Targeted hyperthermia using magnetite cationic liposomes and an
alternating magnetic field in a mouse osteosarcoma model. J Bone
Joint Surg Br. 92:580–585. 2010.
|
|
10
|
Vujaskovic Z, Kim DW, Jones E, et al: A
phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel,
and hyperthermia in locally advanced breast cancer. Int J
Hyperthermia. 26:514–521. 2010.
|
|
11
|
Tang Y and McGoron AJ: Combined effects of
laser-ICG photothermotherapy and doxorubicin chemotherapy on
ovarian cancer cells. J Photochem Photobiol B. 97:138–144.
2009.
|
|
12
|
Fiorillo A, DeRosa G, Giugliano F, et al:
Efficacy of pegylated lyposomal anthracyclines and of
intra-arterial carboplatin and doxorubicin combined with local
hyperthermia in a case of malignant endovascular papillary
angioendothelioma. Curr Drug Deliv. 6:58–61. 2009.
|
|
13
|
Liu B, Yang M, Li X, et al: Enhanced
efficiency of thermally targeted taxanes delivery in a human
xenograft model of gastric cancer. J Pharm Sci. 97:3170–3181.
2008.
|
|
14
|
Michalakis J, Georgatos SD, de Bree E, et
al: Short-term exposure of cancer cells to micromolar doses of
paclitaxel, with or without hyperthermia, induces long-term
inhibition of cell proliferation and cell death in vitro. Ann Surg
Oncol. 14:1220–1228. 2007.PubMed/NCBI
|
|
15
|
Zoul Z, Filip S, Melichar B, et al: Weekly
paclitaxel combined with local hyperthermia in the therapy of
breast cancer locally recurrent after mastectomy - a pilot
experience. Onkologie. 27:385–388. 2004.
|
|
16
|
Mohamed F, Marchettini P, Stuart OA, et
al: Thermal enhancement of new chemotherapeutic agents at moderate
hyperthermia. Ann Surg Oncol. 10:463–468. 2003.
|
|
17
|
de Bree E, Theodoropoulos PA, Rosing H, et
al: Treatment of ovarian cancer using intraperitoneal chemotherapy
with taxanes: from laboratory bench to bedside (Review). Cancer
Treat Rev. 32:471–482. 2006.
|
|
18
|
de Bree E, Rosing H, Michalakis J, et al:
Intraperitoneal chemotherapy with taxanes for ovarian cancer with
peritoneal dissemination (Review). Eur J Surg Oncol. 32:666–670.
2006.
|
|
19
|
Miyata S, Takemura G, Kosai K, et al:
Anti-Fas gene therapy prevents doxorubicin-induced acute
cardiotoxicity through mechanisms independent of apoptosis. Am J
Pathol. 176:687–698. 2010.
|
|
20
|
Kim HS, Lee YS and Kim DK: Doxorubicin
exerts cytotoxic effects through cell cycle arrest and Fas-mediated
cell death. Pharmacology. 84:300–309. 2009.
|
|
21
|
Li S, Zhou Y, Dong Y and Ip C: Doxorubicin
and selenium cooperatively induce Fas signaling in the absence of
Fas/Fas ligand interaction. Anticancer Res. 27:3075–3082. 2007.
|
|
22
|
Drago-Ferrante R, Santulli A, Di Fiore R,
et al: Low doses of paclitaxel potently induce apoptosis in human
retinoblastoma Y79 cells by up-regulating E2F1. Int J Oncol.
33:677–687. 2008.PubMed/NCBI
|
|
23
|
Pires NM, Eefting D, de Vries MR, et al:
Sirolimus and paclitaxel provoke different vascular pathological
responses after local delivery in a murine model for restenosis on
underlying atherosclerotic arteries. Heart. 93:922–927. 2007.
|
|
24
|
Stumm S, Meyer A, Lindner M, et al:
Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas
ligand expression and induces apoptosis which can be inhibited
through the CD40 receptor. Oncology. 66:101–111. 2004.
|
|
25
|
Huisman C, Ferreira CG, Bröker LE, et al:
Paclitaxel triggers cell death primarily via caspase-independent
routes in the non-small cell lung cancer cell line NCI-H460. Clin
Cancer Res. 8:596–606. 2002.
|
|
26
|
Wang X, Gao XH, Li X, et al: Local
hyperthermia induces apoptosis of keratinocytes in both normal skin
and condyloma acuminata via different pathways. Apoptosis.
14:721–728. 2009.
|
|
27
|
Yu DY, Matsuya Y, Zhao QL, et al:
Enhancement of hyperthermia-induced apoptosis by a new synthesized
class of furan-fused tetracyclic compounds. Apoptosis.
12:1523–1532. 2007.
|
|
28
|
Ohguri T, Imada H, Narisada H, et al:
Systemic chemotherapy using paclitaxel and carboplatin plus
regional hyperthermia and hyperbaric oxygen treatment for non-small
cell lung cancer with multiple pulmonary metastases: preliminary
results. Int J Hyperthermia. 25:160–167. 2009.
|
|
29
|
Hulshof MC, Van Haaren PM, Van Lanschot
JJ, et al: Preoperative chemoradiation combined with regional
hyperthermia for patients with resectable esophageal cancer. Int J
Hyperthermia. 25:79–85. 2009.
|
